Tools for Clinical Care and Management of Alzheimers Disease (AD) and Its Comorbidities (R41/R42) | PAR 17 066

Opportunity Information: Apply for PAR 17 066

Tools for Clinical Care and Management of Alzheimers Disease (AD) and Its Comorbidities (R41/R42) is a National Institutes of Health (NIH) funding opportunity from the National Institute on Aging (NIA) designed to support small businesses that are building new, practical technologies to improve the real-world clinical care and day-to-day management of Alzheimers disease and Alzheimers-disease-related dementias (AD/ADRD), including situations where AD occurs alongside other medical conditions. The opportunity is offered under the Small Business Technology Transfer (STTR) program, which is structured to encourage partnerships between an eligible small business and a research institution so that early-stage innovations can move toward products and services that are usable in clinical settings. The grant mechanism is listed as R41/R42, which corresponds to the STTR phased approach: Phase I (R41) typically supports feasibility and proof-of-concept work, while Phase II (R42) supports further development and refinement, with an emphasis on advancing toward commercialization and broader adoption.

The core purpose of the announcement is to drive the development of innovative tools that help clinicians, patients, caregivers, and health systems manage AD/ADRD more effectively. While the brief description does not list specific examples, the emphasis on "clinical care and management" generally points to applied technologies rather than basic science alone. In practice, projects under this theme often include solutions such as clinical decision support tools, digital health platforms, care coordination systems, remote monitoring approaches, caregiver support technologies, symptom tracking and management tools, or other scalable products that can improve assessment, treatment planning, safety, adherence, and ongoing management. The mention of comorbidities signals that NIA is interested not only in dementia-specific needs, but also in technologies that address the complexities of caring for people who have dementia plus other chronic conditions, which can complicate medication management, care planning, and outcomes.

Eligibility is limited to small businesses, consistent with the STTR program requirements, and the announcement clearly restricts non-U.S. participation in key ways. Non-domestic (non-U.S.) entities (foreign institutions) cannot apply as the primary applicant, and non-domestic components of U.S. organizations are not eligible to apply. However, "foreign components" may be allowed under NIH policy, meaning certain parts of the work could potentially be performed outside the United States if they meet NIH rules and are justified, but the applicant organization itself must be an eligible U.S. small business and must follow NIH Grants Policy Statement guidance on what qualifies as an allowable foreign component.

Administratively, this opportunity is categorized as a discretionary grant in the health area and is associated with CFDA number 93.866. The funding opportunity number is PAR 17-066, and the opportunity title indicates it is specifically aligned with tools for clinical care and management rather than discovery research. The source data lists an original closing date of 2019-09-05, and it does not specify an award ceiling or expected number of awards in the provided excerpt, which suggests applicants would need to refer to the full FOA text for current budget limits, project periods, phase-specific caps, and other detailed submission and review requirements. The posting creation date is 2016-12-02, indicating when the announcement record was originally created.

Overall, the opportunity is aimed at accelerating practical, innovative care-management technologies for AD/ADRD through the STTR model, supporting small businesses that can combine product-focused development with research collaboration, while keeping eligibility centered on U.S.-based small business applicants and NIH-compliant arrangements for any allowable foreign components.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "Tools for Clinical Care and Management of Alzheimers Disease (AD) and Its Comorbidities (R41/R42)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.866.
• This funding opportunity was created on 2016-12-02.
• Applicants must submit their applications by 2019-09-05. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for PAR 17 066

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: